Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 July 2024: Editorial  

Editorial: The Global Threats of Increasing Antimicrobial Resistance Require New Approaches to Drug Development, Including Molecular Antimicrobial Adjuvants

Dinah V. Parums1A*

DOI: 10.12659/MSM.945583

Med Sci Monit 2024; 30:e945583

0 Comments

Abstract

0:00

ABSTRACT: Antimicrobial resistance and the associated morbidity and mortality from untreatable common infectious organisms is an increasing threat to global public health. In 2019, the Antimicrobial Resistance Collaborators identified that antimicrobial resistance was directly responsible for up to 1.27 million deaths worldwide and was associated with up to 4.95 million deaths, with low-income and middle-income countries being the most severely affected. In 2019, before the COVID-19 pandemic began, they predicted that antimicrobial resistance could result in 10 million deaths per year by 2050, overtaking cancer as a leading cause of death worldwide. Therefore, there is an urgent need for new approaches to antimicrobial treatment. In June 2024, the findings from researchers at the Ineos Oxford Institute for Antimicrobial Research (IOI) and the Oxford University Department of Pharmacology in the UK reported the use of a small molecule that can work alongside antibiotics to suppress the development of antimicrobial resistance in bacteria. The SOS inhibitor molecule has been called OXF-077. This editorial aims to highlight the global threats from increasing antimicrobial resistance and the urgent need for new molecules that function through novel mechanisms of action, including molecular antimicrobial adjuvants.

Keywords: Editorial, Infection Control, Antimicrobial resistance, Molecular Adjuvant, Infection Control

In the past five years, while attention has focused on the COVID-19 pandemic and its consequences, antimicrobial resistance and the associated morbidity and mortality from untreatable common infectious organisms is an increasing threat to global public health [1,2]. Antimicrobial resistance impacts the prevention and treatment of infections caused by a growing range of bacteria, viruses, parasites, and fungi [3]. Due to media attention and focused public health alerts, there has been awareness of the rates of tuberculosis (TB) and multidrug-resistant TB (MDR TB) have recently increased, and new drug treatment combinations and molecular therapeutic approaches are in development [4,5].

In 2019, the Antimicrobial Resistance Collaborators published a study in the Lancet that involved 204 countries and included data from 471 million patient records to evaluate deaths directly due to and associated with antimicrobial resistance [6]. The Antimicrobial Resistance Collaborators were funded by the Wellcome Trust, the Bill and Melinda Gates Foundation, and the Department of Health and Social Care (DHSC) in the UK, with aid managed by the Fleming Fund [6]. Their study showed that antimicrobial resistance was directly responsible for up to 1.27 million deaths worldwide and was associated with 4.95 million deaths [6]. As a comparison, in 2019, HIV/AIDS and malaria caused 860,000 and 640,000 deaths, respectively [6]. This study also showed that antimicrobial resistance most severely affected low-income and middle-income countries [6]. However, in developed high-income countries, cases and mortality rates from antimicrobial resistance were also increasing at high levels [6]. Twenty-three different types of bacteria were studied, with drug resistance in six types of bacteria that contributed to 3.57 million deaths worldwide [6]. Also, up to 70% of deaths directly due to resistance to antibiotics were associated with previously reliable first-line antibiotics, including beta-lactams and fluoroquinolones [6]. Beta-lactam and fluoroquinolone antibiotics are commonly used to treat urinary tract infections (UTIs), upper respiratory tract infections (URTIs), pneumonia, and bone and joint infections [6]. The Antimicrobial Resistance Collaborators concluded that antimicrobial resistance could make common bacterial infections untreatable worldwide, and they estimated that this could result in 10 million deaths per year by 2050, overtaking cancer as a leading global cause of death [6]. Even in 2019, antimicrobial resistance was identified to be progressing more rapidly than previous estimates and highlighted that the world is running out of effective antibiotics, which means that common bacterial infections are becoming life-threatening again [3,6].

Annually, each November since 2016, the United Nations (UN) General Assembly has organized a week of meetings to promote awareness of the threats posed by antimicrobial resistance to human health, agriculture, and animal health [7]. At the November 2023 meeting, the UN also highlighted the increased loss of animal lives due to untreatable infections and identified that by the year 2050, livestock production could decline by up to 11% due to untreatable microbial infections [7]. The UN has also highlighted the economic effects, which are expected to result in a drop in GDP of at least $3.4 trillion each year by 2030, pushing 24 million more people into extreme poverty [7]. The UN General Assembly will meet again in September 2024 to consider antimicrobial resistance as part of a triple planetary crisis that also includes climate change, biodiversity loss, pollution, and the effects of extreme weather conditions [7]. On 9 May 2024, the World Bank, based in Washington, DC, published a framework for action to address antimicrobial resistance, which it highlighted as a global health and economic threat [8]. The World Bank has also clearly stated an intention to support governments with a World Bank Framework for Action to design interventions focusing on low-income and middle-income countries with 20 intervention areas across the health, water, and agriculture sectors [8].

There are several mechanisms for the development of antimicrobial resistance [9]. Because bacteria replicate rapidly, as part of our co-evolution, they develop mutations that give them a survival advantage in an environment of high antimicrobial use [9]. This situation is more likely to occur when antibiotic treatment is not completed, infection is not eradicated, or antibiotics are inappropriately used [9]. Also, antimicrobial resistance can be spread through the environment, including in the air, food, and drinking water, which may be contaminated by infected patients [9].

Many physical and chemical agents can damage the DNA of cells and microbes, including ultraviolet (UV) light, ionizing radiation, chemical alkylating and oxidizing agents, and cellular byproducts, such as reactive oxygen species (ROS) [10]. In 1974, Miroslav Radman introduced the term the SOS response for the induction of multiple proteins that promote the integrity of DNA and factors that allow for survival and replication even when DNA damage is present [11]. The SOS response repairs damaged DNA in bacteria and increases the rate of genetic mutations, which can accelerate the development of antibiotic resistance [10,11]. Because the SOS response is associated with increased mutagenesis, under normal physiological conditions, it requires complex regulation [10]. A potential molecular approach to controlling antibiotic resistance could be to develop an inhibitor of the mutagenic SOS response [10].

In June 2024, the findings of a study from researchers at the Ineos Oxford Institute for Antimicrobial Research (IOI) and the Oxford University Department of Pharmacology in the UK reported the use of a small molecule that can work alongside antibiotics to suppress the development of antimicrobial resistance in bacteria [12]. The authors studied a series of molecules previously reported to increase the sensitivity of methicillin-resistant Staphylococcus aureus (MRSA) to antibiotics and prevent the MRSA SOS response [12]. They modified the structure of different parts of the molecules and tested their actions against MRSA when given in combination with ciprofloxacin, a fluoroquinolone antibiotic [12]. The most potent SOS inhibitor molecule currently identified has been called OXF-077 [12]. When OXF-077 was combined with a range of antibiotics of different classes, treatment was more effective in preventing MRSA bacterial colony growth [12]. The authors tested the susceptibility and resistance of bacteria treated with ciprofloxacin with and without OXF-077 over a series of days to determine how quickly resistance to the antibiotic developed [12]. This study is the first to identify an inhibitor of the SOS response that can suppress the development of antibiotic resistance in bacteria [12]. A further finding was that when resistant bacteria previously exposed to ciprofloxacin were treated with OXF-077, the sensitivity to the antibiotic was restored to the same level as bacteria that had not developed resistance [12].

New antibiotics that have reached the market in an attempt to overcome antibiotic resistance have been compromised by the rapid emergence of resistant strains or by the selection of bacteria that harbor resistance to related antibiotics [13]. As a result, the pipeline of new antibiotics in clinical development has reached a point of last resort [3,13,14]. Therefore, developing new antimicrobial agents with novel mechanisms of action should also include compounds that can be partnered with existing antibiotics to block resistance mechanisms and enhance efficacy, such as beta-lactamase inhibitors [13]. Currently, an emerging target for developing adjuvants to antibiotics is the bacterial DNA-repair and SOS-response pathways [10,12]. This novel approach may control the upregulation of hypermutation, persistence of resistance, horizontal gene transfer, and bacterial [10,12].

Antimicrobial resistance should be recognized as a growing threat to global health and has the potential to cause even routine medical and surgical procedures too dangerous to be undertaken [15]. Realizing the severity, extent, and consequences of antimicrobial resistance supports the urgent need for new molecules that function through novel mechanisms of action [15]. Therefore, the rapid development of new antibiotics and antimicrobials, with new approaches that target infectious organisms at the molecular level, is urgently required [14,16]. The bacterial DNA repair and SOS-response pathways promote the survival of pathogens in human infections and activate hypermutation and resistance mechanisms [12,15]. Therefore, the bacterial DNA repair and SOS-response pathways are potential targets for new therapeutics [12,15]. Small molecules such as OXF-077 that are under investigation await future clinical development.

Conclusions

The relentless increase in antimicrobial resistance threatens global health, potentially making even routine medical and surgical procedures too dangerous. Realizing the severity, extent, and consequences of antimicrobial resistance supports the urgent need for new molecules that function through novel mechanisms of action, including molecular antimicrobial adjuvants that prevent the development of antimicrobial resistance.

References

1. Haldar J, Confronting the rising threat of antimicrobial resistance: A global health imperative: ACS Infect Dis, 2024; 10(1); 1-2

2. Hassoun-Kheir N, Guedes M, Ngo Nsoga MT, A systematic review on the excess health risk of antibiotic-resistant bloodstream infections for six key pathogens in Europe: Clin Microbiol Infect, 2024; 30(Suppl 1); S14-S25

3. World Health Organization (WHO): Charting a new path forward for global action against antimicrobial resistance May 31, 2024 Available from: https://www.who.int/news-room/events/detail/2024/05/31/default-calendar/charting-a-new-path-forward-for-global-action-against-antimicrobial-resistance

4. Mirzayev F, Viney K, Linh NN, World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update: Eur Respir J, 2021; b57(6); 2003300

5. Parums DV, Editorial: Updates from the World Health Organization (WHO) on global treatment recommendations for drug-susceptible and multidrug-resistant tuberculosis: Med Sci Monit, 2021; 27; e934292

6. Antimicrobial Resistance Collaborators, Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis: Lancet, 2022; 399(10325); 629-55

7. United Nations (UN) Foundation: Charting the course for The AMR agenda in 2024 Nov 28, 2023 Available from: https://unfoundation.org/what-we-do/issues/global-health/global-health-resource-center/the-amr-agenda-in-2024/

8. Rupasinghe N, Machalaba C, Muthee T, Mazimba A: Stopping the grand pandemic: A framework for action – addressing antimicrobial resistance through World Bank operations, 2024, Washington, DC, World Bank Available from: http://hdl.handle.net/10986/41533

9. Huemer M, Mairpady Shambat S, Brugger SD, Zinkernagel AS, Antibiotic resistance and persistence – implications for human health and treatment perspectives: EMBO Rep, 2020; 21(12); e51034

10. Maslowska KH, Makiela-Dzbenska K, Fijalkowska IJ, The SOS system: A complex and tightly regulated response to DNA damage: Environ Mol Mutagen, 2019; 60(4); 368-84

11. Radman M: Mol Environ Asp Mutagen, 1974; 128-42, Springfield, IL, Charles C Thomas Publisher

12. Bradbury JD, Hodgkinson T, Thomas AM, Development of an inhibitor of the mutagenic SOS response that suppresses the evolution of quinolone antibiotic resistance: Chem Sci, 2024, doi: 10.1039/d4sc00995a Available from: https://pubs.rsc.org/en/content/articlelanding/2024/sc/d4sc00995a

13. Allel K, Day L, Hamilton A, Global antimicrobial-resistance drivers: An ecological country-level study at the human-animal interface: Lancet Planet Health, 2023(4); e291-e303

14. World Health Organization (WHO): Antibacterial agents in clinical and preclinical development: An overview and analysis June 14, 2023 Available from: https://iris.who.int/bitstream/handle/10665/376944/9789240094000-eng.pdf

15. Pahil KS, Gilman MSA, Baidin V, A new antibiotic traps lipopolysaccharide in its intermembrane transporter: Nature, 2024; 625(7995); 572-77

16. Walsh TR, Gales AC, Laxminarayan R, Dodd PC, Antimicrobial resistance: Addressing a global threat to humanity: PLoS Med, 2023; 20(7); e1004264

In Press

Clinical Research  

Efficacy of Lung Ultrasound vs Chest X-Ray in Detecting Lung Consolidation and Edema in Premature Infants i...

Med Sci Monit In Press; DOI: 10.12659/MSM.944426  

Laboratory Research  

Three-Dimensional Optical Study on the Effects of Microwave Glazing on Surface Roughness of Zirconia-Reinfo...

Med Sci Monit In Press; DOI: 10.12659/MSM.945130  

Clinical Research  

Prognostic Significance of the Advanced Lung Cancer Inflammation Index in Metastatic Small Cell Lung Cancer...

Med Sci Monit In Press; DOI: 10.12659/MSM.945752  

Review article  

Dangerous Intersection of Alcoholism and Othello Syndrome: A Comprehensive Review of Delusional Jealousy an...

Med Sci Monit In Press; DOI: 10.12659/MSM.945616  

Most Viewed Current Articles

17 Jan 2024 : Review article   6,036,132

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research   1,828,794

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   692,732

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

07 Jan 2022 : Meta-Analysis   257,192

Efficacy and Safety of Light Therapy as a Home Treatment for Motor and Non-Motor Symptoms of Parkinson Dise...

DOI :10.12659/MSM.935074

Med Sci Monit 2022; 28:e935074

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750